About Asthma and its Categories
Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors. The American Academy of Allergy Asthma and Immunology classifies asthma under four categories: exercise-induced asthma, allergic asthma, occupational asthma, and childhood asthma. The Asthma and Allergy Foundation of America classifies asthma into two categories: allergic asthma and non-allergic asthma. It is an incurable disease but can be controlled with the help of diagnosis at the right time, followed by regular therapy.
TechNavio's analysts forecast the Global Asthma Market to grow at a CAGR of 4.50 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Asthma market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various class of drugs used in the treatment of asthma:
• Bronchodilators
• Leukotriene antagonists
• Mast cell stabilizers
• Immunosuppressants
TechNavio's report, the Global Asthma Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Asthma Market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Merck
• Novartis
Other Prominent Vendors
• Abbott
• Actavis
• Amgen
• AptarGroup
• Astellas
• Aurobindo
• Biotest
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• Cytos
• Dainippon Sumitomo
• Dr. Reddy's Laboratories
• Glenmark
• Medicinova
• Mylan
• Ono Pharmaceutical
• Orchid Chemicals and Pharmaceuticals
• Perrigo
• Pfizer
• Ranbaxy
• Rottapharm Madaus
• Skyepharma
• Sosei
• Sunovion
• Teva
• Theravance
• Vectura
Market Driver
• Rise in Prevalence of Disease
• For a full, detailed list, view our report
Market Challenge
• Unknown Etiology of Disease
• For a full, detailed list, view our report
Market Trend
• Popularity of Combination Therapies
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Class of Drugs
07.1 Bronchodilators
07.2 Leukotriene Antagonists
07.3 Mast Cell Stabilizers
07.4 Immunosuppressants
07.5 Combination of LABA/ICS
08. Global Bronchodilators Market
08.1 Market Overview
08.2 Market Size and Forecast
09. Global Leukotriene Antagonists Market
09.1 Market Overview
09.2 Market Size and Forecast
10. Global Mast Cell Stabilizers Market
10.1 Market Overview
10.2 Market Size and Forecast
11. Global Immunosuppressants Market
11.1 Market Overview
11.2 Market Size and Forecast
12. Global Combination of ICS/LABA Market
12.1 Market Overview
12.2 Market Size and Forecast
13. Global Other Asthma Drugs Market
13.1 Market Overview
13.2 Market Size and Forecast
14. Geographical Segmentation
14.1 Global Asthma Market by Geographical Segmentation 2013-2018
14.2 Asthma Market in the US
14.2.1 Market Overview
14.2.2 Market Size and Forecast
14.3 Asthma Market in the Russia
14.3.1 Market Overview
14.3.2 Market Size and Forecast
14.4 Asthma Market in the India
14.4.1 Market Overview
14.4.2 Market Size and Forecast
15. Rate of Incidence and Prevalence
16. Buying Criteria
17. Market Growth Drivers
18. Drivers and their Impact
19. Market Challenges
20. Impact of Drivers and Challenges
21. Market Trends
22. Trends and their Impact
23. Vendor Landscape
23.1 Competitive Scenario
23.1.1 Key News
23.1.2 Mergers and Acquisitions
23.2 Market Share Analysis 2013
23.2.1 AstraZeneca
23.2.2 GlaxoSmithKline
23.2.3 Merck
23.2.4 Novartis
23.2.5 Roche
23.3 Other and Future Prominent Vendors
24. Pipeline Portfolio
25. Key Vendor Analysis
25.1 AstraZeneca plc
25.1.1 Key Facts
25.1.2 Business Description
25.1.3 Business Segmentation
25.1.4 Business Strategy
25.1.5 Revenue by Business Segmentation
25.1.6 Revenue Comparison 2011-2013
25.1.7 Sales Revenue by Geographical Segmentation
25.1.8 Key Developments
25.1.9 SWOT Analysis
25.2 Hoffmann La Roche
25.2.1 Key Facts
25.2.2 Business Overview
25.2.3 Business Segmentation by Revenue 2013
25.2.4 Business Segmentation by Revenue 2012 and 2013
25.2.5 Geographical Segmentation by Revenue 2013
25.2.6 Business Strategy
25.2.7 Recent Developments
25.2.8 SWOT Analysis
25.3 GlaxoSmithKline
25.3.1 Key Facts
25.3.2 Business Overview
25.3.3 Business Segmentation
25.3.4 Business Segmentation by Revenue 2012 and 2013
25.3.5 Sales by Geography
25.3.6 Pipeline Products
25.3.7 Business Strategy
25.3.8 Key Information
25.3.9 SWOT Analysis
25.4 Merck
25.4.1 Key Facts
25.4.2 Business Overview
25.4.3 Business Segmentation by Revenue 2013
25.4.4 Business Segmentation by Revenue 2012 and 2013
25.4.5 Sales by Geography
25.4.6 Business Strategy
25.4.7 Key Developments
25.4.8 SWOT Analysis
25.5 Novartis
25.5.1 Key Facts
25.5.2 Business Overview
25.5.3 Business Segmentation by Revenue 2013
25.5.4 Business Segmentation by Revenue 2012 and 2013
25.5.5 Sales by Geography
25.5.6 Business Strategy
25.5.7 Key Developments
25.5.8 SWOT Analysis
26. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Asthma Market 2014-2018 (US$ million)
Exhibit 3: Global Asthma Market Segmentation by Class of Drugs
Exhibit 4: Global Asthma Market Segmentation by Class of Drugs 2013
Exhibit 5: Global Bronchodilators Market 2013-2018 (US$ million)
Exhibit 6: Global Leukotriene Antagonists Market 2013-2018 (US$ million)
Exhibit 7: Global Mast Cell Stabilizers Market 2013-2018 (US$ million)
Exhibit 8: Global Immunosuppressants Market 2013-2018 (US$ million)
Exhibit 9: Global Combination of ICS/LABA Market 2013-2018 (US$ million)
Exhibit 10: Global Other Asthma Drugs Market 2013-2018 (US$ million)
Exhibit 11: Global Asthma Market by Geographical Segmentation 2013
Exhibit 12: Asthma Market in the US 2013-2018 (US$ million)
Exhibit 13: Asthma Market in Russia 2013-2018(US$ million)
Exhibit 14: Asthma Market in India 2013-2018 (US$ million)
Exhibit 15: Prescription Trend Chart of the Popular Asthma Drugs in the US 2013
Exhibit 16: Global Asthma Market Share Analysis 2013
Exhibit 17: Global Sales of Symbicort 2009-2012 (in US$ million)
Exhibit 18: Geography-wise Sales of Symbicort 2009-2012 (US$ million)
Exhibit 19: Global Sales of Pulmicort 2009-2012 (US$ million)
Exhibit 20: Geography-wise Sales of Pulmicort 2009-2012 (US$ million)
Exhibit 21: Global Sales of Singulair 2011-2013 (US$ million)
Exhibit 22: Global Sales of Dulera 2011-2013 (US$ million)
Exhibit 23: Global Sales Forecast of Dulera 2013-2016 (US$ million)
Exhibit 24: Pipeline Snapshot of Asthma Drugs
Exhibit 25: Sales Forecast of QMF-149 2016-2018 (US$ million)
Exhibit 26: AstraZeneca plc: Business Segmentation
Exhibit 27: AstraZeneca plc: Revenue by Business Segmentation2013
Exhibit 28: AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 29: AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
Exhibit 30: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 31: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 32: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals Division)
Exhibit 33: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics Division)
Exhibit 34: GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 35: GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 36: GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 37: GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 38: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 39: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 40: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 41: Novartis AG: Business Segmentation by Revenue 2013
Exhibit 42: Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 43: Novartis AG: Sales by Geography 2013
